Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy.


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
05 2022
Historique:
pubmed: 4 1 2022
medline: 12 4 2022
entrez: 3 1 2022
Statut: ppublish

Résumé

Cardiovascular disease is a common cause of death in prostate cancer patients. Low testosterone is associated with increased cardiovascular risk in the general male population. We investigated the relationship between serum testosterone, cardiovascular disease and risk factors in androgen-deprivation therapy-naïve prostate cancer patients. We performed a cross-sectional analysis of a subgroup of 1,326 androgen-deprivation therapy-naïve men from RADICAL-PC (Role of Androgen-Deprivation Therapy In CArdiovascular Disease-A Longitudinal Prostate Cancer study) in whom serum testosterone was measured at baseline. RADICAL-PC is a prospective multicenter cohort study of men (2,565) enrolled within 1 year of prostate cancer diagnosis, or within 6 months of commencing androgen-deprivation therapy for the first time. Cardiovascular risk factors, cancer characteristics and total serum testosterone were collected at baseline. Low testosterone was defined as total serum testosterone <11 nmol/L (<320 ng/dL). A Framingham cardiovascular risk score ≥15 was considered high risk for future cardiovascular events. We performed logistic regression to calculate odds ratios for the association between testosterone and cardiovascular risk. Among 1,326 participants (median age 67 years, range 45-93), 553 (42%) had low testosterone. Low testosterone was associated with existing cardiovascular disease, diabetes, elevated hemoglobin A1c, obesity, hypertriglyceridemia, low high-density lipoprotein cholesterol, hypertension and Framingham score >15. Among patients with low testosterone, the odds ratio for high cardiovascular risk was 1.33 (1.02-1.73) after adjusting for ethnicity, education, alcohol use, cancer characteristics, physical activity and body mass index. Among androgen-deprivation therapy-naïve prostate cancer patients, low testosterone is common and associated with increased cardiovascular risk factors.

Identifiants

pubmed: 34978211
doi: 10.1097/JU.0000000000002384
doi:

Substances chimiques

Androgen Antagonists 0
Androgens 0
Testosterone 3XMK78S47O

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1020-1028

Commentaires et corrections

Type : CommentIn

Auteurs

Jehonathan H Pinthus (JH)

Department of Surgery, McMaster University, Hamilton, Ontario, Canada.

Wilhelmina C M Duivenvoorden (WCM)

Department of Surgery, McMaster University, Hamilton, Ontario, Canada.

Laurence Klotz (L)

Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Som D Mukherjee (SD)

Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

D Robert Siemens (DR)

Department of Urology, Queen's University, Kingston, Ontario, Canada.

Tamim Niazi (T)

Division of Radiation Oncology, Jewish General Hospital, McGill University, Montréal, Quebec, Canada.

Vincent Fradet (V)

Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Quebec, Canada.

William Foster (W)

Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Quebec, Canada.

Emmanuelle Duceppe (E)

Department of Medicine, University of Montréal, Montréal, Quebec, Canada.

Daniel Taussky (D)

Department of Radiation Oncology, University of Montréal Health Center, Montréal, Quebec, Canada.

Robert Hamilton (R)

Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

Luke Lavallée (L)

University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Ian Brown (I)

Niagara Health Ontario, Saint Catharines, Ontario, Canada.

Joseph Chin (J)

Division of Urology, Western University, London, Ontario, Canada.

Darin Gopaul (D)

Grand River Regional Cancer Centre, Kitchener, Ontario, Canada.

Anthony Wassef (A)

Division of Cardiology, McMaster University, St Mary's General Hospital, Kitchener, Ontario, Canada.

Wassim Kassouf (W)

Division of Urology, McGill University Health Center, Montréal, Quebec, Canada.

Margot Davis (M)

Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.

Philippe D Violette (PD)

Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

Steve Agapay (S)

Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.

Kumar Balasubramanian (K)

Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.

Rajibul Mian (R)

Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.

Sumathy Rangarajan (S)

Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.

Alp Sener (A)

Division of Urology, Western University, London, Ontario, Canada.

Bobby Shayegan (B)

Department of Surgery, McMaster University, Hamilton, Ontario, Canada.

P J Devereaux (PJ)

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Darryl P Leong (DP)

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH